|
Stock of Cambridge, Mass.-Based Genzyme Tumbles 8 Percent on FDA Delay.
Publication: The Boston Globe (Boston, Massachusetts) (via Knight-Ridder/Tribune Business News) Publication Date: 28-DEC-00 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2000 The Boston Globe
Byline: Naomi Aoki
Dec. 28--Shares of Genzyme Corp. fell as much as 8 percent yesterday, a day after the company said the Food and Drug Administration had asked for additional information on the company's treatment for Fabry disease.
The delay of a decision on approval of the drug Fabrazyme sparked yet another round of speculation among investors about whether Genzyme could beat Transkaryotic Therapies Inc. in the race to become the sole provider of a breakthrough treatment for the rare genetic disorder.
FDA rules require that only one...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from The Boston Globe (Boston, Massachusetts) (via Knight-Ridder/Tribune Business News) |
Waltham, Mass.-Based DSL Provider Digital Broadband to Close.
December 28, 2000
|
Hospitals Cope with Serious Shortage of Pharmacists.
December 28, 2000
|
Maine's Budding Salmon Farms Beset by Federal Regulation, Lawsuits.
December 28, 2000
|
Boston-Area Office Killings Jolt High-Technology Firms.
December 28, 2000
|
Technology Firms' Workplace Informality Seen as Threatening to Some.
December 28, 2000
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
